Stem Cell Treatments for Type 2 Diabetes
Stem Cell and Regenerative Medicine · 30.06.2026 · 10 (1)
DOI: 10.33425/2639-9512.1099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Stem Cell and Regenerative Medicine, online erschienen am 30.06.2026. Verfasst von Jonathan RT Lakey und 12 weiteren Autor:innen.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
Type 1 and type 2 diabetes mellitus (T1D, T2D) represent global health challenges, projected to affect nearly 800 million individuals by 2050. Standard pharmacologic and insulin-based therapies manage hyperglycemia but fail to restore durable endogenous insulin secretion or halt disease progression. Stem cell–based therapies have emerged as a transformative modality, offering the potential for β-cell replacement, immune modulation, and systemic metabolic benefit.
Methods
We conducted a comprehensive narrative review of recent mechanistic advances, bioengineering innovations, and clinical trial data regarding stem cell–derived therapies for diabetes. Data sources included peer-reviewed publications, clinical trial registries, and landmark case studies reporting outcomes of pluripotent stem cell (PSC)-derived β-cell constructs, mesenchymal stem cells (MSCs), hematopoietic stem cells (HSCs), and engineered islet organoids.
Results
Preclinical studies have established robust protocols for differentiating PSCs into glucose-responsive β-cells and isletlike organoids, with engineered enhancements improving graft survival, vascularization, and metabolic resilience. Early-phase clinical trials demonstrate feasibility and efficacy. For example, autologous approaches achieve long-term insulin independence in a T2D patient using induced pluripotent stem cell–derived islets, whereas allogeneic constructs restored C-peptide production and eliminated severe hypoglycemia in T1D patients, with the majority achieving insulin independence. Gene-edited, hypoimmune islets in preclinical primates demonstrated long-term insulin independence without immunosuppression, highlighting the feasibility of off-the-shelf platforms. Further, engineered MSCs secreting GLP-1 and FGF21 improved glycemia and lipid metabolism in models, suggesting systemic cardiometabolic benefit beyond insulin replacement.
Conclusions
Stem cell–based therapies for diabetes have progressed from theoretical promise to early clinical reality. Evidence now supports durable β-cell function, improved glycemic control, and reduced insulin dependence in both T1D and T2D. Remaining challenges include ensuring long-term graft stability, vascularization, and immune protection, as well as establishing scalable, GMPcompliant manufacturing. Next-generation trials integrating immune-evasive engineering, vascularized scaffolds, and personalized autologous sources are poised to redefine diabetes care, shifting the paradigm from chronic management toward durable disease modification and potential cure.
Zitieren
APA
Lakey, J. R., Bluguermann, C., Jenkins, I., Casazza, K., Learnhardt, W., Robinson, B., Mutto, A., Andrade, D., Medina-Nolasco, A., Gutiérrez-Contreras, A., Vos, P. D., Bramblett, R., & Gutierrez-Castrellon, P. (2026). Stem Cell Treatments for Type 2 Diabetes. Stem Cell and Regenerative Medicine, 10(1). https://doi.org/10.33425/2639-9512.1099
Vancouver
Lakey JR, Bluguermann C, Jenkins I, Casazza K, Learnhardt W, Robinson B, et al. Stem Cell Treatments for Type 2 Diabetes. Stem Cell and Regenerative Medicine. 2026;10(1). doi:10.33425/2639-9512.1099
BibTeX
@article{Lakey2026,
author = {Lakey, Jonathan RT and Bluguermann, Carolina and Jenkins, Ian and Casazza, Krista and Learnhardt, Waldemar and Robinson, Bradley and Mutto, Adrian and Andrade, Diana and Medina-Nolasco, Araceli and Gutiérrez-Contreras, Andrea and Vos, Paul de and Bramblett, Robert and Gutierrez-Castrellon, Pedro},
title = {Stem Cell Treatments for Type 2 Diabetes},
journal = {Stem Cell and Regenerative Medicine},
year = {2026},
volume = {10},
number = {1},
doi = {10.33425/2639-9512.1099}
}
EUVIMED